Recognizing affordability as essential, Dr. Sajan accepts all private insurance plans for MTF breast augmentation, significantly reducing financial barriers. Patients using insurance typically pay ...

Prof. Mike Chan’s lifelong dedication to autism treatment is transforming the landscape of bioregenerative medicine. His ...

The Option has an exercise price of $1.18 per share, which is equal to the closing price of PacBio common stock on March 31, 2025 (the “Effective Date”). The shares subject to the Option are scheduled ...

About Syndax Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj ® ...

The stock options are subject to the terms and conditions of Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of ...

Additional details are included in, and the description above is qualified in its entirety by, AIM’s Current Report on Form 8-K filed with the SEC on April 4, 2025, which will be made available under ...

Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted an inducement award consisting of non-qualified stock options to ...

The inducement grants were approved by ORIC’s Compensation Committee of the Board of Directors, as required by Nasdaq Rule 5635 (c) (4), and were granted as a material inducement to employment in ...

Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635 (c) (4).

Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients ...

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of ...